Physician profile
Eric Smith
NPI 1780633859
$16,320.17
in general payments reported to CMS, 2019-2025
57 companies · $2,738 in 2025
The $2,738 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,657 · 2020: $1,339 · 2021: $2,197 · 2022: $2,769 · 2023: $2,417 · 2024: $2,202 · 2025: $2,738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,316 · Education: $41.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,315.71 |
| Education | $41.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,306.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,797.04 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,547.74 | 2019-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals Lp | $1,417.93 | 2019-2025 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $1,290.12 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $914.66 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $781.32 | 2019-2025 | Jardiance, Synjardy, Spiriva |
| Abbvie INC. | $715.99 | 2019-2025 | Qulipta, Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $710.04 | 2021-2025 | |
| Exact Sciences Corporation | $473.72 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $324.48 | 2021-2025 | Freestyle Libre 3, Infinity |
| Novartis Pharmaceuticals Corporation | $306.94 | 2021-2024 | |
| Amarin Pharma, INC. | $289.98 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $262.62 | 2023-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $238.88 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.